1. Home
  2. KMDA

as of 02-20-2026 4:00pm EST

$8.80
+$0.14
+1.62%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Founded: 1990 Country:
Israel
Israel
Employees: N/A City: N/A
Market Cap: 458.6M IPO Year: 2013
Target Price: $13.00 AVG Volume (30 days): 68.1K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
2.27%
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $5.54 - $9.08 Next Earning Date: 01-01-0001
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 14.79% Revenue Growth (next year): 11.38%
P/E Ratio: 24.59 Index: N/A
Free Cash Flow: N/A FCF Growth: -42.40%

AI-Powered KMDA Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold
Model Accuracy: 69.03%
69.03%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Kamada Ltd. News

KMDA Breaking Stock News: Dive into KMDA Ticker-Specific Updates for Smart Investing

All KMDA News

Share on Social Networks: